Ambrx Biopharma Inc. (AMAM)
$12.65
Rating:
Recommendation:
-
| Symbol | AMAM |
|---|---|
| Price | $12.65 |
| Beta | -2.364 |
| Volume Avg. | 1.04M |
| Market Cap | 791.153M |
| Shares () | - |
| 52 Week Range | 6.55-16.285 |
| 1y Target Est | - |
| DCF Unlevered | AMAM DCF -> | |
|---|---|---|
| DCF Levered | AMAM LDCF -> | |
| ROE | -34.98% | Strong Sell |
| ROA | -25.55% | Sell |
| Operating Margin | - | |
| Debt / Equity | 4.34% | Neutral |
| P/E | 30.12 | Strong Buy |
| P/B | 3.25 | Strong Buy |
Latest AMAM news
About
Download (Excel)Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.